16:10 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; lung cancer Cell culture studies identified a triple KRAS/NRAS/HRAS inhibitor that could help treat KRAS-mutant colorectal cancer and NRAS-mutant non-small cell lung cancer (NSCLC). Screening of a small molecule library, structure-based optimization of...
22:49 , Aug 10, 2018 |  BC Extra  |  Preclinical News

New approach could identify Ras-blocking small molecules

With an eye on historically undruggable cancer target Ras, a University of Oxford team and colleagues devised a way to find small molecules that have the same qualities as Ras inhibitors too large to access...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on June 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform,...
18:50 , Jul 11, 2018 |  BC Extra  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million on June 28. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten...
18:41 , Jun 28, 2018 |  BC Extra  |  Financial News

Kura, Zafgen price follow-ons

Kura Oncology Inc. (NASDAQ:KURA) and Zafgen Inc. (NASDAQ:ZFGN) each priced follow-ons of at least $60 million Thursday. Kura raised $67 million through the sale of 4 million shares at $16.75 in an offering underwritten by Leerink....
23:31 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus; viral infection Cell culture studies suggest two sialylated IGHA1 isotype mAbs targeting HA could help treat influenza and Newcastle disease. The IGHA1 isotype mAbs consist of the variable regions of two previously identified...
21:12 , Mar 7, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Engineered viruses A method for enhancing viral sensitivity to host IFN could be used to generate highly immunogenic, live virus-based vaccines against infection. The approach involves using saturation mutagenesis and next-generation sequencing to compare genomes...
23:23 , Feb 28, 2018 |  BC Innovations  |  Translation in Brief

Interferon non-interference

Researchers from UCLA have developed a method to enhance the immunogenicity of live virus-based vaccines by inactivating the virus’ ability to evade interferon-mediated host immunity. Having shown proof-of-concept for an influenza A vaccine, the team...
23:53 , Feb 22, 2018 |  BC Innovations  |  Product R&D

Shooting for the universe

CureVac AG is bringing a new modality to the race for a universal flu vaccine with an mRNA program backed by a grant from the Bill & Melinda Gates Foundation. While the company believes its...